Revelation Biosciences (REVB)
(Delayed Data from NSDQ)
$2.18 USD
+0.04 (1.87%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $2.18 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Revelation Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 12 | 5 | 0 | 1 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 12 | 5 | 0 | 1 | 0 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 48 | 74 | 0 |
Total Assets | 12 | 6 | 48 | 74 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 1 | 0 | 0 |
Accounts Payable | 1 | 1 | 2 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 3 | 2 | 0 | 0 |
Total Current Liabilities | 6 | 4 | 5 | 0 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 3 | 3 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 48 | 66 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 4 | 56 | 69 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 32 | 26 | 0 | 5 | 0 |
Retained Earnings | -25 | -25 | -8 | 0 | 0 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 7 | 1 | -8 | 5 | 0 |
Total Liabilities & Shareholder's Equity | 12 | 6 | 48 | 74 | 0 |
Total Common Equity | 7 | 1 | -8 | 5 | 0 |
Shares Outstanding | 0.20 | 0.00 | 0.00 | 0.00 | NA |
Book Value Per Share | 33.25 | 1.05 | -7.82 | 5.00 | 0.00 |
Fiscal Year End for Revelation Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 12 | 14 | 16 | 18 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 12 | 14 | 16 | 18 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 12 | 14 | 16 | 18 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 1 | 1 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 3 | 3 | 6 |
Total Current Liabilities | NA | 6 | 5 | 5 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 6 | 5 | 5 | 8 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 32 | 32 | 32 | 29 |
Retained Earnings | NA | -25 | -23 | -21 | -19 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 7 | 9 | 11 | 10 |
Total Liabilities & Shareholder's Equity | NA | 12 | 14 | 16 | 18 |
Total Common Equity | 0 | 7 | 9 | 11 | 10 |
Shares Outstanding | 1.60 | 0.20 | 0.20 | 0.20 | 0.10 |
Book Value Per Share | 0.00 | 33.25 | 44.10 | 57.05 | 100.20 |